| John W Shuck, MD | |
|
540 S Governors Ave Ste 201, Dover, DE 19904-3530 | |
| (302) 672-4600 | |
| (302) 672-4606 |
| Full Name | John W Shuck |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 47 Years |
| Location | 540 S Governors Ave Ste 201, Dover, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689641086 | NPI | - | NPPES |
| 1689641086 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | C10006635 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayhealth Hospital, Kent Campus | Dover, DE | Hospital |
| Bayhealth Hospital, Sussex Campus | Milford, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bayhealth Medical Center, Inc | 1658364740 | 288 |
News Archive
Long-term exercise appears to be beneficial for Spinal Muscular Atrophy (SMA) like mice, suggesting a potential of active physiotherapy for patient care; according to a study published today in the Journal of Physiology.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
› Verified 9 days ago
| Entity Name | Bayhealth Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467546135 PECOS PAC ID: 1658364740 Enrollment ID: O20040405001600 |
News Archive
Long-term exercise appears to be beneficial for Spinal Muscular Atrophy (SMA) like mice, suggesting a potential of active physiotherapy for patient care; according to a study published today in the Journal of Physiology.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
› Verified 9 days ago
| Entity Name | Bayhealth Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1285809509 PECOS PAC ID: 1658364740 Enrollment ID: O20081010000398 |
News Archive
Long-term exercise appears to be beneficial for Spinal Muscular Atrophy (SMA) like mice, suggesting a potential of active physiotherapy for patient care; according to a study published today in the Journal of Physiology.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
› Verified 9 days ago
| Entity Name | Bayhealth Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1417473935 PECOS PAC ID: 1658364740 Enrollment ID: O20190429001388 |
News Archive
Long-term exercise appears to be beneficial for Spinal Muscular Atrophy (SMA) like mice, suggesting a potential of active physiotherapy for patient care; according to a study published today in the Journal of Physiology.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
› Verified 9 days ago
| Entity Name | Bayhealth Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1063938439 PECOS PAC ID: 1658364740 Enrollment ID: O20190501000077 |
News Archive
Long-term exercise appears to be beneficial for Spinal Muscular Atrophy (SMA) like mice, suggesting a potential of active physiotherapy for patient care; according to a study published today in the Journal of Physiology.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John W Shuck, MD 640 S State St, Mail Code 3055, Dover, DE 19901-3530 Ph: (302) 480-1688 | John W Shuck, MD 540 S Governors Ave Ste 201, Dover, DE 19904-3530 Ph: (302) 672-4600 |
News Archive
Long-term exercise appears to be beneficial for Spinal Muscular Atrophy (SMA) like mice, suggesting a potential of active physiotherapy for patient care; according to a study published today in the Journal of Physiology.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs.
› Verified 9 days ago
Theodore Conrad Ang Tan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 810 New Burton Rd, Suite 3, Dover, DE 19904 Phone: 302-730-0554 Fax: 302-730-1175 | |
Francis Lim, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 640 S State St, Dover, DE 19901 Phone: 419-276-1194 | |
Safwan Muhammad, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 640 S State St, Dover, DE 19901 Phone: 879-022-5410 | |
Dr. Wai Wai Lin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1058 S Governors Ave Ste 101, Dover, DE 19904 Phone: 302-401-1500 Fax: 302-672-6450 | |
Abdul Muhaymin Siyal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 720 S Queen St, Dover, DE 19904 Phone: 302-734-7834 Fax: 302-734-7847 | |
Dr. Daniel L. Fisher, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 333 Red Tail Dr, Dover, DE 19904 Phone: 302-943-8040 | |
Dr. Manmeet Brar, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1198 S Governors Ave Ste B100, Dover, DE 19904 Phone: 302-734-3227 Fax: 302-734-0391 |